Tracking a Two-Drug combo to keep skin cancer at bay
NCT ID NCT04961619
Summary
This study observed how well a two-drug combination (dabrafenib and trametinib) worked for patients with high-risk melanoma after their tumors were surgically removed. Researchers followed 39 patients in Turkey to see how long they stayed cancer-free, how long they took the medication, and what side effects they experienced. The goal was to understand how this treatment performs in everyday medical practice, not in a controlled clinical trial.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Novartis Investigative Site
Antalya, Konyaalti, 07070, Turkey (Türkiye)
-
Novartis Investigative Site
Edirne, Merkez, 22030, Turkey (Türkiye)
-
Novartis Investigative Site
Bursa, Nilufer, 16059, Turkey (Türkiye)
-
Novartis Investigative Site
Diyarbakır, Sur, 21280, Turkey (Türkiye)
-
Novartis Investigative Site
Istanbul, Uskudar, 34668, Turkey (Türkiye)
-
Novartis Investigative Site
Adana, Yuregir, 1230, Turkey (Türkiye)
-
Novartis Investigative Site
Ankara, 06520, Turkey (Türkiye)
-
Novartis Investigative Site
Izmir, 35100, Turkey (Türkiye)
-
Novartis Investigative Site
Kecioren Ankara, 06010, Turkey (Türkiye)
Conditions
Explore the condition pages connected to this study.